560 results on '"Bonadonna, Patrizia"'
Search Results
2. Mast cell conditions and drug allergy: when to suspect & how to manage
3. Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal
4. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
5. Risk Factors for Severe Sting Reactions and Side Effects During Venom Immunotherapy
6. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
7. Venom Anaphylaxis: Decision Points for a More Aggressive Workup
8. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
9. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
10. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
11. Antiacid drugs: Proton Pump Inhibitors and H2 Receptor Antagonists
12. Drug Hypersensitivity and Clonal Mast Cell Disorders
13. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis
14. Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
15. Alpha-gal syndrome
16. Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
17. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
18. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
19. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
20. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
21. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
22. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
23. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
24. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
25. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
26. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
27. Mast cell conditions and drug allergy: when to suspect and how to manage.
28. Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond
29. Reductions in Polypharmacy for Patients with Indolent Systemic Mastocytosis on Avapritinib
30. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study
31. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
32. Prevalence of Pol d 1 Sensitization in Polistes dominula Allergy and Its Diagnostic Role in Vespid Double-Positivity
33. Venom Allergy and Management in Mastocytosis
34. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis
35. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
36. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
37. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
38. Alpha-gal syndrome: when treatment of hypovolemic shock can lead to anaphylaxis.
39. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
40. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper
41. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
42. Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy
43. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management
44. Mastocytosis as a risk factor for insect venom allergy
45. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry
46. Management of Patients During Acute Reaction Induced by Drugs
47. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
48. Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study
49. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology
50. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.